## Guglielmo Verona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1485407/publications.pdf

Version: 2024-02-01

840776 940533 20 495 11 16 citations h-index g-index papers 21 21 21 749 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
2	Clinical ApoAâ€IV amyloid is associated with fibrillogenic signal sequence. Journal of Pathology, 2021, 255, 311-318.	4.5	4
3	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 2021, 12, 7112.	12.8	13
4	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, 2020, 295, 11379-11387.	3.4	12
5	L444P Gba1 mutation increases formation and spread of $\hat{l}$ ±-synuclein deposits in mice injected with mouse $\hat{l}$ ±-synuclein pre-formed fibrils. PLoS ONE, 2020, 15, e0238075.	2.5	20
6	Glucocerebrosidase deficiency promotes release of $\hat{l}_{\pm}$ -synuclein fibrils from cultured neurons. Human Molecular Genetics, 2020, 29, 1716-1728.	2.9	35
7	Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 206-207.	3.0	6
8	Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. Clinical Chemistry and Laboratory Medicine, 2020, 58, 948-957.	2.3	20
9	Title is missing!. , 2020, 15, e0238075.		O
10	Title is missing!. , 2020, 15, e0238075.		O
10	Title is missing!. , 2020, 15, e0238075.  Title is missing!. , 2020, 15, e0238075.		0
11	Title is missing!. , 2020, 15, e0238075.	6.4	0
11 12	Title is missing!. , 2020, 15, e0238075.  Title is missing!. , 2020, 15, e0238075.  Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and	6.4	0
11 12 13	Title is missing!. , 2020, 15, e0238075.  Title is missing!. , 2020, 15, e0238075.  Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. Journal of Medicinal Chemistry, 2019, 62, 8274-8283.  Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological		0 0 25
11 12 13	Title is missing!. , 2020, 15, e0238075.  Title is missing!. , 2020, 15, e0238075.  Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. Journal of Medicinal Chemistry, 2019, 62, 8274-8283.  Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.  A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue	3.4	0 0 25 68
11 12 13 14	Title is missing!. , 2020, 15, e0238075.  Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. Journal of Medicinal Chemistry, 2019, 62, 8274-8283.  Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.  A specific nanobody prevents amyloidogenesis of D76N β2-microglobulin in vitro and modifies its tissue distribution in vivo. Scientific Reports, 2017, 7, 46711.  Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding	3.4	0 0 25 68 18

#	Article	IF	CITATIONS
19	A novel mechanoâ€enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Molecular Medicine, 2015, 7, 1337-1349.	6.9	109
20	The H50Q Mutation Induces a 10-fold Decrease in the Solubility of α-Synuclein. Journal of Biological Chemistry, 2015, 290, 2395-2404.	3.4	65